Genomic aberrations in borderline ovarian tumors

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Micci, Francesca ^a   Haugom, Lisbeth ^a   Ahlquist, Terje ^a,b   Andersen, Hege K ^a   Abeler, Vera M ^a   Davidson, Ben ^a,c   Trope, Claes G ^a   Lothe, Ragnhild A ^a,b   Heim, Sverre ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ALLELIC IMBALANCE; ARTICLE; CHROMOSOME 12; CHROMOSOME 12Q; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 16P; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 19P; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 2Q; CHROMOSOME 3Q; CHROMOSOME 6Q; CHROMOSOME 7; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME G BAND; CHROMOSOME HIGH RESOLUTION BANDING ANALYSIS; CHROMOSOME LOSS; CHROMOSOME PAIRING; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC GAIN; GENETIC SIMILARITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; KARYOTYPING; METASTASIS; MICROSATELLITE INSTABILITY; MOLECULAR CLONING; OVARY TUMOR; GENETICS; HUMAN CHROMOSOME; PATHOLOGY; TUMOR CELL CULTURE;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MICROSATELLITE INSTABILITY; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 77949413172     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-21     Document Type: Article

References (50)

1. Tavassoli FA, Devilee P. Tumors of the breast and female genital organs - World Health Organization Classification of Tumors 2003, Lyon: IARC Press.
2. Tibiletti MG, Bernasconi B, Furlan D, Bressan P, Cerutti R, Facco C, Franchi M, Riva C, Cinquetti R, Capella C, Taramelli R. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms. Clin Cancer Res 2001, 7:3404-3409.
3. Mitelman database of chromosome aberrations in cancer. , http://cgap.nci.nih.gov/Chromosomes/Mitelman
4. Knoerr-Gaertner H, Schuhmann R, Kraus H, Uebele-Kallhardt B. Comparative cytogenetic and histologic studies on early malignant transformation in mesothelial tumors of the ovary. Hum Genet 1977, 35:281-297. 10.1007/BF00446621, 557448.
5. Crickard K, Marinello MJ, Crickard U, Satchidanand SK, Yoonessi M, Caglar H. Borderline malignant serous tumors of the ovary maintained on extracellular matrix: evidence for clonal evolution and invasive potential. Cancer Genet Cytogenet 1986, 23:135-143.
6. Yang-Feng TL, Li SB, Leung WY, Carcangiu ML, Schwartz PE. Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer 1991, 48:678-681. 10.1002/ijc.2910480508, 2071229.
7. Jenkins RB, Bartelt D, Stalboerger P, Persons D, Dahl RJ, Podratz K, Keeney G, Hartmann L. Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet 1993, 71:76-86. 10.1016/0165-4608(93)90205-Z, 8275457.
8. Thompson FH, Liu Y, Emerson J, Weinstein R, Makar R, Trent JM, Taetle R, Alberts DS. Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma. Genes Chromosomes Cancer 1994, 10:262-266. 10.1002/gcc.2870100407, 7522540.
9. Pejovic T, Iosif CS, Mitelman F, Heim S. Karyotypic characteristics of borderline malignant tumors of the ovary: trisomy 12, trisomy 7, and r(1) as nonrandom features. Cancer Genet Cytogenet 1996, 92:95-98. 10.1016/S0165-4608(96)00169-0, 8976364.
10. Tharapel SA, Qumsiyeh MB, Photopulos G. Numerical chromosome abnormalities associated with early clinical stages of gynecologic tumors. Cancer Genet Cytogenet 1991, 55:89-96. 10.1016/0165-4608(91)90240-U, 1913613.
11. Deger RB, Faruqi SA, Noumoff JS. Karyotypic analysis of 32 malignant epithelial ovarian tumors. Cancer Genet Cytogenet 1997, 96:166-173. 10.1016/S0165-4608(96)00327-5, 9216725.
12. Wolf NG, bdul-Karim FW, Farver C, Schrock E, du MS, Schwartz S. Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 1999, 25:307-315. 10.1002/(SICI)1098-2264(199908)25:4<307::AID-GCC1>3.0.CO;2-1, 10398423.
13. Blegen H, Einhorn N, Sjovall K, Roschke A, Ghadimi BM, McShane LM, Nilsson B, Shah K, Ried T, Auer G. Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. Int J Gynecol Cancer 2000, 10:477-487. 10.1046/j.1525-1438.2000.00077.x, 11240718.
14. Hauptmann S, Denkert C, Koch I, Petersen S, Schluns K, Reles A, Dietel M, Petersen I. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 2002, 33:632-641. 10.1053/hupa.2002.124913, 12152163.
15. Hu J, Khanna V, Jones MM, Surti U. Genomic imbalances in ovarian borderline serous and mucinous tumors. Cancer Genet Cytogenet 2002, 139:18-23. 10.1016/S0165-4608(02)00603-9, 12547152.
16. Staebler A, Heselmeyer-Haddad K, Bell K, Riopel M, Perlman E, Ried T, Kurman RJ. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol 2002, 33:47-59. 10.1053/hupa.2002.30212, 11823973.
17. Helou K, Padilla-Nash H, Wangsa D, Karlsson E, Osterberg L, Karlsson P, Ried T, Knutsen T. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet Cytogenet 2006, 170:1-8. 10.1016/j.cancergencyto.2006.04.010, 16965948.
18. Micci F, Weimer J, Haugom L, Skotheim RI, Grunewald R, Abeler VM, Silins I, Lothe RA, Trope CG, Arnold N, Heim. Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. Genes Chromosomes Cancer 2009, 48:184-193. 10.1002/gcc.20628, 18973136.
19. Mandahl N. Methods in solid tumors. Human Cytogenetics - a practical approach, vol II, Malignancy and acquired abnormalities 1992, 155-187. Oxford: IRL Press, Rooney DE, Czepulkovski BH.
20. ISCN An International System for Human Cytogenetic Nomenclature 2005, Basel: Karger S, ISCN.
21. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual 2009, Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
22. Kearny L, Hammomd DW. Molecular Cytogenetic Technologies. Human Cytogenetics - malignancy and acquired abnormalities 2009, 129-163. Oxford: Oxford University Press, Rooney DE, 3.
23. Brandal P, Bjerkehagen B, Heim S. Molecular cytogenetic characterization of tenosynovial giant cell tumors. Neoplasia 2004, 6:578-583. 10.1593/neo.04202, 1531662, 15548367.
24. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992, 258:818-821. 10.1126/science.1359641, 1359641.
25. Micci F, Teixeira MR, Haugom L, Kristensen G, Abeler VM, Heim S. Genomic aberrations in carcinomas of the uterine corpus. Genes Chromosomes Cancer 2004, 40:229-246. 10.1002/gcc.20038, 15139002.
26. Kirchhoff M, Gerdes T, Rose H, Maahr J, Ottesen AM, Lundsteen C. Detection of chromosomal gains and losses in comparative genomic hybridization analysis based on standard reference intervals. Cytometry 1998, 31:163-173. 10.1002/(SICI)1097-0320(19980301)31:3<163::AID-CYTO3>3.0.CO;2-M, 9515715.
27. Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, Lundsteen C, Bryndorf T, Kryger-Baggesen N, Christensen L, Engelholm SA, Philip J. Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer 1999, 24:144-150. 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9, 9885981.
28. Ribeiro FR, Diep CB, Jeronimo C, Henrique R, Lopes C, Eknaes M, Lingjaerde OC, Lothe RA, Teixeira MR. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 2006, 45:154-163. 10.1002/gcc.20279, 16235241.
29. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257.
30. Wu Q, Lothe RA, Ahlquist T, Silins I, Trope CG, Micci F, Nesland JM, Suo Z, Lind GE. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer 2007, 6:45. 10.1186/1476-4598-6-45, 1964763, 17623056.
31. Tangir J, Loughridge NS, Berkowitz RS, Muto MG, Bell DA, Welch WR, Mok SC. Frequent microsatellite instability in epithelial borderline ovarian tumors. Cancer Res 1996, 56:2501-2505.
32. Shih YC, Kerr J, Hurst TG, Khoo SK, Ward BG, Chenevix-Trench G. No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms. Gynecol Oncol 1998, 69:210-213. 10.1006/gyno.1998.5014, 9648589.
33. Haas CJ, Diebold J, Hirschmann A, Rohrbach H, Schmid S, Lohrs U. Microsatellite analysis in serous tumors of the ovary. Int J Gynecol Pathol 1999, 18:158-162.
34. Gras E, Catasus L, Arguelles R, Moreno-Bueno G, Palacios J, Gamallo C, Matias-Guiu X, Prat J. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 2001, 92:2829-2836. 10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3, 11753956.
35. Sanz Casla MT, Vidaurreta LM, Almansa dL I, Tresserra F, Lopez ML, Maestro ML, Dexeus S. Role of microsatellite instability in borderline ovarian tumors. Anticancer Res 2003, 23:5139-5141.
36. Wolf NG, Farver C, bdul-Karim FW, Schwartz S. Analysis of microsatellite instability and X-inactivation in ovarian borderline tumors lacking numerical abnormalities by comparative genomic hybridization. Cancer Genet Cytogenet 2003, 145:133-138. 10.1016/S0165-4608(03)00093-1, 12935925.
37. Micci F, Heim S. Tumors of the Female Genital Organs. Cancer Cytogeentics - Chromosomal and Molecular Genetic Aberrations of Tumor Cells 2009, 519-575. New Jersey: Wiley-Blackwell, Heim S, Mitelman F, 3.
38. Osterberg L, Akeson M, Levan K, Partheen K, Zetterqvist BM, Brannstrom M, Horvath G. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet 2006, 167:103-108. 10.1016/j.cancergencyto.2006.01.009, 16737908.
39. Godwin AK, Vanderveer L, Schultz DC, Lynch HT, Altomare DA, Buetow KH, Daly M, Getts LA, Masny A, Rosenblum N. A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet 1994, 55:666-677. 1918278, 7942844.
40. Phillips NJ, Zeigler MR, Deaven LL. A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. Cancer Lett 1996, 102:85-90. 10.1016/0304-3835(96)04169-9, 8603384.
41. Saretzki G, Hoffmann U, Rohlke P, Psille R, Gaigal T, Keller G, Hofler H, Loning T, Petersen I, Dietel M. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer 1997, 80:1241-1249. 10.1002/(SICI)1097-0142(19971001)80:7<1241::AID-CNCR7>3.0.CO;2-N, 9317174.
42. Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ, Godwin AK. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 1996, 56:1997-2002.
43. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat 2003, 21:285-291. 10.1002/humu.10181, 12619114.
44. Shelling AN, Cooke IE, Ganesan TS. The genetic analysis of ovarian cancer. Br J Cancer 1995, 72:521-527. 2033888, 7669555.
45. Skilling JS, Sood A, Niemann T, Lager DJ, Buller RE. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996, 13:117-123.
46. Skomedal H, Kristensen GB, Abeler VM, Borresen-Dale AL, Trope C, Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 1997, 181:158-165. 10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8, 9120719.
47. Caduff RF, Svoboda-Newman SM, Ferguson AW, Johnston CM, Frank TS. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 1999, 23:323-328. 10.1097/00000478-199903000-00012, 10078924.
48. Schuyer M, Henzen-Logmans SC, Burg ME, Fieret JH, Derksen C, Look MP, Meijer-van Gelder ME, Klijn JG, Foekens JA, Berns EM. Genetic alterations in ovarian borderline tumours and ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol 1999, 82:147-150. 10.1016/S0301-2115(98)00217-6, 10206406.
49. Cornelis RS, Neuhausen SL, Johansson O, Arason A, Kelsell D, Ponder BA, Tonin P, Hamann U, Lindblom A, Lalle P, et al. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 1995, 13:203-210. 10.1002/gcc.2870130310, 7669740.
50. Israeli O, Gotlieb WH, Friedman E, Goldman B, Ben-Baruch G, viram-Goldring A, Rienstein S. Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH. Gynecol Oncol 2003, 90:629-636. 10.1016/S0090-8258(03)00375-5, 13678737.